Trial ID or NCT#

NCT03724175

Status

recruiting iconRECRUITING

Purpose

The cause of Inflammatory bowel disease (IBD) is unknown, but intestinal bacteria-involved in the production of molecules that impact health-are widely accepted to play a key role. A significant proportion of IBD patients with pouches (surgically created rectums after the diseased colon is removed) continue to have inflammation similar to their previous disease. Only a few microbes are known to have the capability to modify primary bile acids (PBAs) made by the liver to secondary bile acids (SBAs). SBAs are some of the most common metabolites in the colon and play key roles in several diseases. In this study the investigators will investigate if ursodeoxycholic acid (UDCA) may reduce inflammatory markers and improve quality of life (as assessed by validate survey) in those subjects with active antibiotic refractory or antibiotic dependent pouchitis.

Official Title

The Role of Secondary Bile Acids in Intestinal Inflammation

Eligibility Criteria

Ages Eligible for Study: 18 Years to 70 Years
Sexes Eligible for Study: All
Accepts Healthy Volunteers: No

Investigator(s)

Sidhartha Sinha
Sidhartha Sinha
Gastroenterologist, Inflammatory bowel disease specialist
Assistant Professor of Medicine (Gastroenterology and Hepatology)

Contact us to find out if this trial is right for you.

CONTACT

Sidharta Sinha, MD